41 results about "Colonic Carcinoma" patented technology

The invention discloses a chalcone analogue containing 2-methyl-4-oxo-quinazoline-6-base, shown in a general formula (I), wherein the definitions of Ar1 and Ar2 are shown in the description. Besides, the invention further discloses a preparation method and a medical composition of the chalcone analogue containing 2-methyl-4-oxo-quinazoline-6-base. The chalcone analogue containing 2-methyl-4-oxo-quinazoline-6-base, shown in the general formula (I), has an inhibiting effect on cell proliferation of human colonic carcinoma (HCT-116) and human breast cancer (MCF-7), and can be used as an antitumor drug.

The invention discloses a high-grade composite nourishing flour and noodle, which is characterized by the following: adopting walnut pulp, soy and wheat as raw material, inhibiting leukemia, colon cancer, lung carcinoma and gastric cancer.

The invention discloses an application of a cynanchum ascyrifolium extract in the preparation of tumor cell multidrug resistance reversal agents. The cynanchum ascyrifolium extract reverses the drug-resistant actions of human gastric tumor multidrug resistance cells, human colonic carcinoma multidrug resistance cells and human lung carcinoma multidrug resistance cells on clinical commonly used drugs such as taxol, adriamycin, 5-fluorouracil and cis-platinum. The cynanchum ascyrifolium extract disclosed by the invention is simple and convenient in preparation method, is combined with antitumor drugs to be applied to clinical application and has wide application prospects, and the curative effect of chemotherapy is improved.

The invention provides a method for evaluating the biosecurity of 76 nm nano silver on the base of intestinal epithelial cells. According to the method, cell lines of human colon carcinoma epithelial cells Caco-2 are selected as an object of study, nano zinc oxide (90.81 nm) with higher cytotoxicity is taken as a positive control, normal cells without the nano material are taken as a blank control, and the cytotoxicity of the nano material is preliminarily explored by an AO/EB double staining method and a CCK-8 method. The oxidative damage effect and the possible mechanism of nano silver on cells are studied by an oxidative stress method through detecting the influence of emission of ROS, SOD and GSH in the cells Caco-2. The result shows that 76.29nm silver particles (smaller than 200 mu g/ml) don't influence the activity of the cells Caco-2 obviously and cause no oxidative stress damage on the cells Caco-2, but the oxidation resistance of the cells is enhanced and is up to the highest level when the concentration of nano silver is 50 mu g/ml.

The invention discloses an oral medicine for colorectal carcinoma fistulation later-stage nursing, and its preparation method. The medicine comprises 50-80 parts of Semen Phaseoli, 35-70 parts of Holothuria leucospilota, 40-90 parts of Meliosma fordii, 30-60 parts of roxburgh rose root, 24-60 parts of baccate sedge herb, 32-56 parts of shrubalthea root, 18-30 parts of radix paeoniae rubra, 22-46 parts of Inonotus cuticularis (Bull.: Fr.) Karst., 18-34 parts of konjac, 8-20 parts of Ajuga pantantha, 20-38 parts of Coriolus versicolor(L.ex Fr.)Quel., 20-50 parts of Cinnamomum wilsonii Gamble and 45-86 parts of Begonia yunnanensis Levl.. The medicine has strict composition and reasonable compatibility, has the efficacies of heat clearing, blood activating, diuresis inducing, channel freeing, intestine widening, qi rectifying, intestine damp heat removing, intestine moistening, bowel relaxing, blood circulation invigorating, bleeding stopping, qi moving, pain relieving, and stomach and intestine distention qi mitigating, comprises Chinese herbal medicines benefiting the rehabilitation of alimentary canal tumors and adjusting the immune function, can condition colorectal carcinoma patients subjected to fistulation, and has a good nursing efficacy on later-stage fistulization stoma complications.

The invention relates to an application of a bacillus subtilis protein AMEP412 with an amino acid sequence as shown in SEQ ID NO: 1 in inhibition of tumor cell proliferation. The tumor cells are any one of liver cancer cells, cervical cancer cells, pancreatic cancer cells, colon cancer cells, prostate cancer cells, lung cancer cells, uterine squamous cell carcinoma cells, gastric adenocarcinoma cells, malignant glioblastoma cells and breast cancer cells. According to the invention, the inhibition function of the protein AMEP412 on tumor cells is found; the protein can generate an inhibition effect on 10 kinds of tumor cells, has selective specificity on inhibition effects on different kinds of tumor cells, and has the best effect on breast cancer cells; transcriptomics research finds that the protein AMEP412 can cause the change of a plurality of pathways related to apoptosis and death in tumor cells, and a new material is accumulated for inhibiting the activity of the tumor cells.

A method of treating a solid tumor in a mammal by inhibiting angiogenesis, including administering to the mammal which has a solid tumor selected from the group consisting of breast carcinoma, lung carcinoma, prostate carcinoma, colon carcinoma, ovarian carcinoma, neuroblastoma, central nervous system tumor, multiform glioblastoma and melanoma; a composition including brassinosteroids of general formula (I)

wherein can be a single or double bond and the configurations of carbon atoms C22 and C23 respectively linked to the substituents HO are S for both carbon atoms and a pharmaceutically acceptable additive.

The present invention is based on the key roles played by Hedgehog proteins in the regulation of homeostasis of the adult intestinal epithelium. Ihh is expressed in the adult mammalian colon and provides a lineage-instructive signal and regulates colonic epithelial morphogenesis in a compartmental fashion. Loss of Ihh expression precedes morphological change in colon tumorigenesis, i.e. carcinogenesis, and Ihh was absent in HT-29 colon carcinoma cells. Treatment of cancerous HT-29 cells with exogenous Hedgehog protein restored their differentiation. Ihh thus plays a pivotal role in the maintenance of colonic epithelial homeostasis in the differentiation of the GI tract cells and is essential for the enrolment of these GI tract cells on the Death program thus maintaining homeostasis to avoid or treat carcinogenesis. In addition, in gastric cancer expression of Shh is lost and loss of Shh expression precedes morphological changes in the parietal cells of the stomach. Shh is specifically expressed in fundic glands as well as in gastric heterotopia in the esophagus in Meckel's diverticulum. Shh thus has a unique role as a morphogen in fundic gland homeostasis. The present invention relates to methods in which a source of Hedgehog proteins is used prophylactically or therapeutically to maintain homeostasis of the adult intestinal epithelium. In particular the invention relates methods whereby sources of Hedgehog protein are used to prevent or treat carcinogenesis in adult gastric and colonic tissues. The invention also relates to Hedgehog-based method of diagnosing susceptibility for or the presence of carcinogenesis in the adult GI tract, particularly in gastric and colonic tissues. The invention further provide for compositions to be used in the Hedgehog-based methods of diagnosing, preventing and treating epithelial tumorigenesis in the adult GI tract.

The invention discloses a kit for left colonic carcinoma detection. The kit comprises an aptamer capable of detecting KLK6 protein and can be used for screening left colonic carcinoma. The kit has the advantages of being high in sensitivity, low in cost and suitable for large-scale screening.

The invention relates to the technical field of biological medicines, firstly provides a folic acid modified Pluronic P85 copolymer and also relates to a preparation method of a 5-fluorouracil anti-cancer nano drug. Experiments show that the 5-fluorouracil nano drug prepared by adopting the folic acid modified Pluronic P85 copolymer can be used for obviously inhibiting tumour cell growth; meanwhile, in a mouse colonic carcinoma hepatic metastasis model, formation of colonic carcinoma liver metastases can be obviously reduced, and lifetime of a mouse can be obviously prolonged, so that the folic acid modified Pluronic P85 copolymer has a good effect on resisting colonic carcinoma hepatic metastasis, and the 5-fluorouracil anti-cancer nano drug is hopeful to be an anti-tumour drug with a clinical application prospect.

The present invention relates to the field of diagnosis and treatment of the colorectal cancer, and in particular to the use of aurora-B kinase and survivin in the diagnosis of the colorectal cancer. The invention aims to provide application of Aurora B and Survivin in preparation of a colorectal cancer diagnosis kit. Expression of nuclear Aurora B and cytoplasmic Survivin are involved in lymph node metastasis of the colon cancer, and both nuclear Aurora B and cytoplasmic Survivin are closely related to lymph node metastasis of the colon cancer. Nuclear Aurora B and cytoplasmic Survivin are diagnostic markers and therapeutic targets for colorectal cancer.

The invention belongs to the fields of genetic engineering and genetic modification of mouse cells, and particularly relates to an EpCAM gene humanized mouse tumor cell model as well as a constructionmethod and application thereof. A mouse EpCAM gene is knocked out by virtue of a CRISPR technique, and meanwhile, the humanized EpCAM gene is inserted into a mouse colon cancer cell CT26 through lentivirus infection. The EpCAM gene humanized mouse tumor cell model can be used for evaluating antibody tumor pesticide effect and has important guiding significance to clinic effects of developed drugs. Meanwhile, the EpCAM gene humanized mouse tumor cell model is an ideal mouse tumor cell model for evaluating the safety of anti-EpCAM antibody drugs and can be used for carrying out preclinical in-vivo evaluation on toxicological immunocell therapies of EpCAM antibody drugs and EpCAM-CAR T, EpCAM-CAR NK, so that a market blank is filled up.

The invention relates to a 5-aryl nicotinamide LSD1/HDAC double-target inhibitor and a preparation method and application thereof in preparation of antitumor drugs, and belongs to the technical field of medicinal chemistry. The compound has the following general formula shown in the specification, wherein R1 is preferably OH, CH3 and H; and R2 is preferably OH, OCH3, F, CN, H and CH3. The compound has relatively strong inhibitory activity to LSD1 and HDAC1, and the IC50 of most compounds to HDAC1 is less than 10 nM, which is superior to that of a positive drug SAHA. The in-vitro anti-tumor activity IC50 of a plurality of compounds on a human colon cancer HCT-116 cell strain, a human gastric cancer MGC-803 cell strain and human leukemia THP-1, MOLT-4 and MV4: 11 cell strains is less than 1.0 mu M, and the in-vitro anti-tumor activity of the compound I-4 on THP-1 is 6 times that of SAHA. The compound provides a basis for research and development of LSD1/HDAC double-target inhibitor drugs.